Clinical Trial Update: REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation [Phase 2, Phase 3]

View source ↗

Summary

The REDEL trial is evaluating reduced elective nodal radiation dose to mitigate toxicity in anal cancer across Phase 2 and Phase 3, and the study is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Snippet

Sponsor: University of Cincinnati | Conditions: Anal Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING